Clene (CLNN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Clene (CLNN) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.03 of bullish evidence against -0.48 bearish.

Clene last closed at $3.86, -0.52% on the session.

Against the IVW growth benchmark the position is -1.32% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for CLNN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Clene in the 98th percentile on return on equity, where 100 is best.

Clene is classified under Health Care / Biotechnology, with a market capitalisation of $55.15M.

StockMap tracks Clene as the 308th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Clene ranks 363rd of 381 in the group, against a group median of -0.08.